In conclusion, the present study demonstrates that the combination of melatonin and IDO1 inhibitors display synergistic effects when combined with a tumor-specific immunotherapy and, therefore, represents a new and promising perspective for the control of HPV-associated tumors, and possibly other cancer types. This evidence concerns the gene IDO1 and neoplasm.